TITLE

Endovascular Stroke Treatments and IV t-PA May Have Similar Outcomes

AUTHOR(S)
Zoler, Mitchel L.
PUB. DATE
March 2013
SOURCE
Neurology Reviews;Mar2013, Vol. 21 Issue 3, p28
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article focuses on a randomized trail performed to study treatment procedures for patients suffering from acute ischemic stroke. This study was presented at the 2013 International Stroke Conference and showed that the effect of endovascular therapy had no effect in treatment of intracranial artery blockages. The normal procure adopted includes movement to endovascular procedure if the tissue plasminogen activator (t-PA) fails to remove the cranial blockage.
ACCESSION #
86412312

 

Related Articles

  • Combination of Eptifibatide and t-PA May Be Safe to Administer for Stroke. Greb, Erik // Neurology Reviews;Mar2013, Vol. 21 Issue 3, p29 

    The article focuses on a randomized trail performed to study the treatment procedures for patients suffering from acute ischemic stroke. This study was presented at the 2013 International Stroke Conference and showed that if the patients were treated with tissue plasminogen activator (t-PA) and...

  • Minimal sufficient balance-a new strategy to balance baseline covariates and preserve randomness of treatment allocation. Zhao, Wenle; Hill, Michael D.; Palesch, Yuko // Statistical Methods in Medical Research;Dec2015, Vol. 24 Issue 6, p989 

    In many clinical trials, baseline covariates could affect the primary outcome. Commonly used strategies to balance baseline covariates include stratified constrained randomization and minimization. Stratification is limited to few categorical covariates. Minimization lacks the randomness of...

  • Endovascular Therapy May Provide No Benefit When Combined With t-PA. Mechcatie, Elizabeth // Neurology Reviews;Mar2013, Vol. 21 Issue 3, p1 

    The article focuses on a study conducted by Joseph Broderick, Chair of the Department of Neurology at the University of Cincinnati and lead investigator of the International management of Stroke (IMS) III Study. The study found that treatment of patients with acute ischemic stroke with IV tissue...

  • Endovascular revascularization results in IMS III: intracranial ICA and M1 occlusions. Tomsick, Thomas A.; Yeatts, Sharon D.; Liebeskind, David S.; Carrozzella, Janice; Foster, Lydia; Goyal, Mayank; von Kummer, Ruediger; Hill, Michael D.; Demchuk, Andrew M.; Jovin, Tudor; Yan, Bernard; Zaidat, Osama O.; Schonewille, Wouter; Engelter, Stefan; Martin, Renee; Khatri, Pooja; Spilker, Judith; Palesch, Yuko Y.; Broderick, Joseph P. // Journal of NeuroInterventional Surgery;Nov2015, Vol. 7 Issue 11, p795 

    Background Interventional Management of Stroke III did not show that combining IV recombinant tissue plasminogen activator (rt-PA) with endovascular therapies (EVTs) is better than IV rt-PA alone. Objective To report efficacy and safety results for EVT of intracranial internal carotid artery...

  • Acute Ischemic Stroke and Timing of Treatment. Radecki, Ryan P. // JAMA: Journal of the American Medical Association;11/6/2013, Vol. 310 Issue 17, p1855 

    A letter to the editor is presented in response to an article about the association of time to tissue-type plasminogen activator (tPA) treatment and outcomes of stroke.

  • Acute Ischemic Stroke and Timing of Treatment. Saver, Jeffrey L.; Fonarow, Gregg C.; Schwamm, Lee H. // JAMA: Journal of the American Medical Association;11/6/2013, Vol. 310 Issue 17, p1856 

    A response to a letter to the editor about an article on the association of time to tissue-type plasminogen activator (tPA) treatment and outcomes of stroke is presented.

  • Alteplase for ischaemic stroke: concerns raised in UK.  // Reactions Weekly;Sep2014, Vol. 1518 Issue 1, p4 

    The article focuses on the evidence about the use of alteplase, a tissue plasminogen activator (t-PA), for the treatment of acute ischaemic stroke.

  • Improvement in Thrombolytic Therapy Administration in Acute Stroke with Feedback. Ghrooda, Esseddeeg; Alcock, Susan; Jackson, Alan C. // Canadian Journal of Neurological Sciences;Nov2012, Vol. 39 Issue 6, p789 

    Background: The benefits of intravenous recombinant tissue plasminogen activator (rt-PA) in acute ischemic stroke is time dependent. Guidelines recommend a door-to-needle (DTN) time of less than 60 minutes. Methods: A retrospective audit of 730 stroke charts from 2008 - 2011 was conducted at...

  • Clinical Neuroprotective Drugs for Treatment and Prevention of Stroke. Kikuchi, Kiyoshi; Uchikado, Hisaaki; Morioka, Motohiro; Murai, Yoshinaka; Tanaka, Eiichiro // International Journal of Molecular Sciences;Jun2012, Vol. 13 Issue 6, p7739 

    Stroke is an enormous public health problem with an imperative need for more effective therapies. In therapies for ischemic stroke, tissue plasminogen activators, antiplatelet agents and anticoagulants are used mainly for their antithrombotic effects. However, free radical scavengers,...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics